SOURCE: The Hydropothecary Corporation

medical marijuana thc

May 16, 2017 08:11 ET

Hydropothecary Announces Reintroduction of Products for Sale and Voluntary Product Recall

GATINEAU, QC--(Marketwired - May 16, 2017) - The Hydropothecary Corporation (TSX VENTURE: THCX) ("THCX" or the "Company") is pleased to announce that it has resumed selling cannabis products from certain lots after completion of additional testing following the Company's previously announced voluntary stop-sale on its products.

Lot retesting was carried out to ensure there was no presence of myclobutanil, a pesticide approved for use in agriculture (e.g. apples trees, almonds, strawberries, vegetables, soybeans and grape vines), but not for use on cannabis. Results of the lots now released for sale show no sign of contamination. Health Canada has been provided with these test results. The Company will continue to test product using its previously implemented voluntary testing program and is supportive of Health Canada's mandatory testing initiative announced on May 5, 2017. The Company will continue to keep patients informed and updated on test results. With the resumed selling, the Company currently has 13 of 14 products available for sale. Registered clients can order their products as normal, through the webstore or by calling the Company's 24/7 line at 1-844-406-1852. Those wishing to register can do so online or by calling the Company.

"Hydropothecary has always put our customers' health and safety first, through providing well grown and rigorously tested medical cannabis of the highest quality. Today's announcement that we have lifted the voluntary stop-sale is a direct result of our quality assurance efforts. We will continue to strive for the highest possible standards for all of our products and to put patients first," said Sebastien St-Louis, Co-founder and CEO.

Based on the completion of other, additional screening, the Company is currently voluntarily recalling fourteen lots of medical cannabis, which were supplied between February 1, 2016 and May 1, 2017, due to the detection of myclobutanil. These products have tested positive for trace amounts over 0.01 parts per million, but no more than 0.08 parts per million. The recalled lots are lots numbered 45, 46, 47, 54, 58, 59, 102, 109, 123, 127, 128, 129, 148 and 150.

Health Canada has deemed this a Type III recall, defined as "a situation in which the use of, or exposure to a product is not likely to cause any adverse health consequences." All affected clients are being notified.

The source of the contamination is unknown at this time, however the Company is carrying out an in-depth investigation and has completed sampling across its facility. A total of 254 samples have been sent for independent testing, including live plants (flowering, vegetating, mothers), previously-tested dried cannabis lots, production inputs, cultivation equipment, and grow area wall scrapings. Initial results indicate the contamination occurred during older production, but has not exceeded 0.08 parts per million.

In addition, the Company is conducting additional screening on all lots produced since Hydropothecary's inception, as part of its commitment to the highest health and safety standards.

"We will remain resolute in ensuring that our clients have the utmost confidence in all Hydropothecary products and will keep everyone informed of our findings through our daily updates" Mr. St-Louis said.

About The Hydropothecary Corporation

The Hydropothecary Corporation is an authorized licensed producer and distributor of medical marijuana licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary provides naturally grown and rigorously tested medical marijuana of uncompromising quality. Hydropothecary's branding, marijuana product offering, patient service standards and product pricing are consistent with THCX's positioning as a premium brand for a legal source for medical marijuana within this new marketplace. In addition to medical marijuana production and sales, Hydropothecary explores various research and development opportunities for cannabinoid extracts, drugs and combinatory chemistry. In addition, the company is investigating the development and patenting of novel technologies related to medical marijuana, as well as the import and export of medical marijuana.

Forward-Looking Information

This press release contains forward-looking information which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • For further information, please contact:
    Jennifer Smith
    Manager of Financial Reporting and Investor Relations
    The Hydropothecary Corporation
    1-866-438-THCX (8429)
    invest@THCX.com
    www.THCX.com